

## Cambodia: Cambodia Rapid Immunization Support Project under the Asia Pacific Vaccine Access Facility

Project Name			
•	Cambodia Rapid Immunization Support Project under the Asia Pacific Vaccine Access Facility		
Project Number	55104-001		
Country / Economy	Cambodia		
Project Status	Approved		
Project Type / Modality of Assistance	Loan		
Source of Funding / Amount	Loan 4173-CAM: Cambodia Rapid Immunization Support Project under the Asia Pacific Vaccine Access Facilit	ty	
	Concessional ordinary capital resources lending	US\$ 95.00 million	
	Loan 8416-CAM: Cambodia Rapid Immunization Support Project under the Asia Pacific Vaccine Access Facilii	ty	
	Asian Infrastructure Investment Bank	US\$ 50.00 million	
Strategic Agendas	Inclusive economic growth Regional integration		
Drivers of Change	Gender Equity and Mainstreaming Knowledge solutions Partnerships		
Sector / Subsector	Health / Disease control of communicable disease		
Gender Equity and Mainstreaming	Effective gender mainstreaming		
Description	The project is aligned with the following impacts: (i) severity of the pandemic reduced, lives saved, and social disruptions minimized; and (ii negative health, social, and economic effects of the COVID-19 pandemic mitigated. The project will have the following outcome: about 10.1 million people in target populations vaccinated or boosted against COVID-19.  The project will support the procurement of an estimated 14.5 million doses of safe and effective COVID-19 vaccines via the APVAX rapid response component (RRC) and the AIIB loan. It will contribute to the government's goal of strengthening population immunity by providing booster doses and primary vaccination to children below 5. The project will also help to develop and disseminate social and gender-inclusive guidelines to ensure equitable coverage of COVID-19 vaccination		
Project Rationale and Linkage to Country/Regional Strategy	Cambodia was largely successful in controlling coronavirus disease (COVID-19) in 2020. An outbreak in February of 2021, however, led to widespread closures of schools and business and a lockdown in Phnom Penh and other heavily impacted areas until the fourth quarter of 2021. As of 3 January 2022, Cambodia had 120,516 confirmed COVID-19 cases and 3,014 deaths. Cambodia launched its vaccination campaign on 10 February 2021 and has administered over 28 million doses, covering over 80% of its total population of 16.7 million. It has also provided booster doses to 21.8% of its population. Despite the country's success in rolling-out COVID-19 vaccination, its health system remains highly vulnerable to a surge in new infections linked to variants such as Delta and Omicron.		
Impact	Severity of the pandemic reduced, lives saved, and social disruptions minimized Negative health, social, and economic effects of the COVID-19 pandemic mitigated		
impact			
Impact Project Outcome			
Project Outcome	Negative health, social, and economic effects of the COVID-19 pandemic mitigated	COVID-19	
Project Outcome Description of Outcome		COVID-19	
Project Outcome Description of Outcome Progress Toward Outcome	Negative health, social, and economic effects of the COVID-19 pandemic mitigated	COVID-19	
Project Outcome Description of Outcome Progress Toward Outcome Implementation Progress	Negative health, social, and economic effects of the COVID-19 pandemic mitigated  Target populations vaccinated against	COVID-19	
Project Outcome  Description of Outcome  Progress Toward Outcome  Implementation Progress  Description of Project Outputs	Negative health, social, and economic effects of the COVID-19 pandemic mitigated  Target populations vaccinated against COVID-19 vaccines deployed	COVID-19	
Project Outcome  Description of Outcome  Progress Toward Outcome  Implementation Progress  Description of Project Outputs  Status of Implementation Progress (	Negative health, social, and economic effects of the COVID-19 pandemic mitigated  Target populations vaccinated against  COVID-19 vaccines deployed  (Outputs, Activities, and Issues)	COVID-19	
Project Outcome  Description of Outcome  Progress Toward Outcome  Implementation Progress  Description of Project Outputs  Status of Implementation Progress (	Negative health, social, and economic effects of the COVID-19 pandemic mitigated  Target populations vaccinated against COVID-19 vaccines deployed	COVID-19	
Project Outcome  Description of Outcome  Progress Toward Outcome  Implementation Progress  Description of Project Outputs  Status of Implementation Progress ( Geographical Location	Negative health, social, and economic effects of the COVID-19 pandemic mitigated  Target populations vaccinated against  COVID-19 vaccines deployed  (Outputs, Activities, and Issues)	COVID-19	
Project Outcome  Description of Outcome  Progress Toward Outcome  Implementation Progress  Description of Project Outputs  Status of Implementation Progress ( Geographical Location  Safeguard Categories	Negative health, social, and economic effects of the COVID-19 pandemic mitigated  Target populations vaccinated against  COVID-19 vaccines deployed  (Outputs, Activities, and Issues)	COVID-19	
Project Outcome  Description of Outcome  Progress Toward Outcome  Implementation Progress  Description of Project Outputs  Status of Implementation Progress ( Geographical Location  Safeguard Categories  Environment	Negative health, social, and economic effects of the COVID-19 pandemic mitigated  Target populations vaccinated against  COVID-19 vaccines deployed  (Outputs, Activities, and Issues)  Nation-wide	COVID-19	
Project Outcome  Description of Outcome  Progress Toward Outcome  Implementation Progress  Description of Project Outputs  Status of Implementation Progress ( Geographical Location  Safeguard Categories  Environment  nvoluntary Resettlement	Negative health, social, and economic effects of the COVID-19 pandemic mitigated  Target populations vaccinated against  COVID-19 vaccines deployed  (Outputs, Activities, and Issues)  Nation-wide	COVID-19	
Project Outcome  Description of Outcome  Progress Toward Outcome  Implementation Progress  Description of Project Outputs  Status of Implementation Progress ( Geographical Location  Safeguard Categories	Negative health, social, and economic effects of the COVID-19 pandemic mitigated  Target populations vaccinated against  COVID-19 vaccines deployed  (Outputs, Activities, and Issues)  Nation-wide  C C C C	COVID-19	
Project Outcome Description of Outcome Progress Toward Outcome Implementation Progress Description of Project Outputs Status of Implementation Progress ( Geographical Location  Safeguard Categories Environment Involuntary Resettlement Indigenous Peoples  Summary of Environmental and Soc	Negative health, social, and economic effects of the COVID-19 pandemic mitigated  Target populations vaccinated against  COVID-19 vaccines deployed  (Outputs, Activities, and Issues)  Nation-wide  C C C C	COVID-19	
Project Outcome  Description of Outcome  Progress Toward Outcome  Implementation Progress  Description of Project Outputs  Status of Implementation Progress ( Geographical Location  Safeguard Categories  Environment  Involuntary Resettlement  Indigenous Peoples  Summary of Environmental and Socientifications	Negative health, social, and economic effects of the COVID-19 pandemic mitigated  Target populations vaccinated against  COVID-19 vaccines deployed  (Outputs, Activities, and Issues)  Nation-wide  C C C C	COVID-19	
Project Outcome  Description of Outcome  Progress Toward Outcome  Implementation Progress  Description of Project Outputs  Status of Implementation Progress ( Geographical Location  Safeguard Categories  Environment  Involuntary Resettlement  Indigenous Peoples	Negative health, social, and economic effects of the COVID-19 pandemic mitigated  Target populations vaccinated against  COVID-19 vaccines deployed  (Outputs, Activities, and Issues)  Nation-wide  C C C C	COVID-19	
Project Outcome Description of Outcome Progress Toward Outcome Implementation Progress Description of Project Outputs Status of Implementation Progress ( Geographical Location  Safeguard Categories Environment Involuntary Resettlement Indigenous Peoples  Summary of Environmental and Society involuntary Resettlement Involuntary Resettlement Involuntary Resettlement	Negative health, social, and economic effects of the COVID-19 pandemic mitigated  Target populations vaccinated against  COVID-19 vaccines deployed  (Outputs, Activities, and Issues)  Nation-wide  C C C C C C Cial Aspects	COVID-19	

## **Business Opportunities**

Procurement Mill be undertaken with simplified and expedient procedures permitted under the ADB Procurement Policy (2017, as amended from time to time) and Procurement Regulations for ADB Borrowers (2017, as amended from time to time).

Responsible ADB Officer	Elfving, Rikard N.
Responsible ADB Department	Southeast Asia Department
Responsible ADB Division	Human and Social Development Division, SERD
Executing Agencies	Ministry of Health No. 151-153, Avenue Kampuchea Krom 1537 Phnom Penh Kingdom of Cambodia

Timetable	
Concept Clearance	
Fact Finding	29 Mar 2021 to 02 Apr 2021
MRM	28 May 2021
Approval	15 Feb 2022
Last Review Mission	
Last PDS Update	15 Feb 2022

## Loan 4173-CAM

Financing Plan		Loan Utilization			
	Total (Amount in US\$ million)	Date	ADB	Others	Net Percentage
Project Cost	103.50	Cumulative Contract Awards		Awards	
ADB	95.00	-	0.00	0.00	%
Counterpart	8.50	Cumulative Disbursements			
Cofinancing	0.00	-	0.00	0.00	%

## Loan 8416-CAM

Financing Plan		Loan Utilization			
	Total (Amount in US\$ million)	Date	ADB	Others	Net Percentage
Project Cost	50.00	Cumulative Contract Awards		wards	
ADB	0.00	-	0.00	0.00	%
Counterpart	0.00	Cumulative Disbursements			
Cofinancing	50.00	-	0.00	0.00	%

Project Page	https://www.adb.org/projects/55104-001/main
Request for Information	http://www.adb.org/forms/request-information-form?subject=55104-001
Date Generated	16 February 2022

ADB provides the information contained in this project data sheet (PDS) solely as a resource for its users without any form of assurance. Whilst ADB tries to provide high quality content, the information are provided "as is" without warranty of any kind, either express or implied, including without limitation warranties of merchantability, fitness for a particular purpose, and non-infringement. ADB specifically does not make any warranties or representations as to the accuracy or completeness of any such information.